Spotlight On... Lilly moves toward psoriasis showdown with Novartis in EU; Boehringer's Ofev cuts acute exacerbations in IPF patients; Amarin reports Vascepa leap; and more...

Look out, Novartis ($NVS). Eli Lilly ($LLY) is now one step closer in the EU to challenging the Swiss pharma's new psoriasis standout, Cosentyx, with its own next-gen therapy, ixekizumab. The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has backed a go-ahead for the therapy, and regulators typically green-light recommended approvals within three months. More from FierceBiotech

@FiercePharma: Look out, drugmakers: NICE is taking the reins of England's Cancer Drugs Fund. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Short on label expansions, Pfizer nabs FDA OK for new, once-daily Xeljanz. Story | Follow @CarlyHFierce

> Boehringer Ingelheim's Ofev cut the risk of acute exacerbations by around 50% in idiopathic pulmonary fibrosis patients. Release

> Ireland's Amarin ($AMRN) reported a 62% leap in fourth-quarter sales of fish-oil drug Vascepa. Report

> Belgium's UCB expects further expansion of its top and bottom lines this year after its three newer drugs drove earnings by more than expected in 2015. Report

> UBS forecasts that HIV drug unit ViiV Healthcare will contribute almost half of GlaxoSmithKline's ($GSK) operating profits by 2020. More

> A hearing has begun in India on whether Gilead Sciences' ($GILD) hepatitis C cure sofosbuvir is based on novel science and is entitled to a patent. Release

> The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of Alprolix from Biogen ($BIIB) and Sobi for treatment of hemophilia B. Release

Medical Device News

@FierceMedDev: ICYMI: Boston Scientific's Brazilian operations under investigation, as co-founder to depart. Story | Follow @FierceMedDev

@EmilyWFierce: Intel hops on the precision medicine bandwagon with new projects for 2016. News | Follow @EmilyWFierce

> FDA warns of unintentional head movement during surgery despite use of skull clamp. Story

> Boston upstart raises $46M, makes acquisition for translational imaging in biopharma R&D. More

Biotech News

@FierceBiotech: Charities and pharma decry 'disgraceful' changes to England's Cancer Drugs Fund. Story | Follow @FierceBiotech

@JohnCFierce: Glad to see the top trending story yesterday was the Exicure profile. Doesn't always happen with little biotechs. Story | Follow @JohnCFierce

@DamianFierce: Wired is getting into dystopian fiction. Wired story | Follow @DamianFierce

> FierceBiotech Radio on the FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation.' Listen

> Report: Fatal French trial ignored preclinical warning signs. News

> Lilly rolls toward EU approval with a potential psoriasis blockbuster. More

And Finally... This week's $72 million verdict against Johnson & Johnson ($JNJ) in a U.S. case alleging links between talc-based powder and ovarian cancer doesn't necessarily mean future plaintiffs will be able to convince juries that the product caused their illnesses. More

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.